Comparative Analysis of Oxiris and CytoSorb

A detailed exploration of mechanisms, clinical use, and outcomes

Highlights

• Mechanism and Design: Oxiris utilizes an AN69-based membrane with chemical modifications that allow both endotoxin and cytokine removal, while CytoSorb uses polymer beads focused on cytokine and broad-spectrum inflammatory mediator elimination.
• Clinical Integration: Oxiris is engineered for seamless integration with continuous renal replacement therapy (CRRT) circuits, making it ideal for septic patients with acute kidney injury; in contrast, CytoSorb offers flexibility, being usable within various extracorporeal circuits.
• Clinical Outcomes: Studies indicate that Oxiris may reduce mortality, shorten ICU stays, and improve hemodynamic parameters due to combined endotoxin and cytokine clearance, whereas CytoSorb excels in aggressive cytokine removal in hyperinflammatory conditions.

Introduction

In the realm of critical care, especially in the treatment of sepsis, septic shock, and hyperinflammatory conditions, extracorporeal blood purification devices have emerged as valuable adjuncts to standard therapies. Two such devices, Oxiris and CytoSorb, have seen increasing application in clinical settings, each harnessing unique technology and design to address the complex pathophysiology of sepsis. This comprehensive analysis explores their mechanisms, clinical integration, effectiveness, and outcomes to aid in decision making for practitioners who must tailor therapies to specific patient needs.

Mechanisms of Action

Oxiris

Design and Functionality

Oxiris is built on an AN69 membrane base which is modified with polyethyleneimine (PEI) and a heparin coating. This modified surface facilitates ionic binding, allowing the device to adsorb both endotoxins and cytokines simultaneously. Endotoxins are lipopolysaccharides on the outer membrane of gram-negative bacteria, and their removal is paramount when addressing sepsis from such infections. The integration of a heparin coating not only minimizes thrombogenicity, thus enhancing biocompatibility, but also confers local anticoagulant properties, reducing clot formation within the extracorporeal circuit. The design enables Oxiris to be seamlessly incorporated into continuous renal replacement therapy (CRRT) devices, making it particularly advantageous in patients suffering from acute kidney injury alongside severe infections.

Adsorption Mechanism

The underlying mechanism of Oxiris involves ionic interactions that target and bind inflammatory mediators, both endotoxins and cytokines, from the blood. This dual functionality allows for a more holistic approach to blood purification in septic and hyperinflammatory conditions. By removing endotoxins, Oxiris plays a crucial role in modulating the inflammatory cascade triggered by bacterial infections.

CytoSorb

Design and Functionality

CytoSorb, on the other hand, is a hemoadsorber device primarily developed to combat the cytokine storm associated with sepsis, acute respiratory distress syndrome (ARDS), and other inflammatory conditions. The device employs porous polymer beads designed to have a large active surface area. These beads interact with blood components through hydrophobic interactions, van der Waals forces, and charge-induced mechanisms, enabling the absorption of a wide variety of mid-molecular weight compounds. The spectrum extends beyond cytokines to include chemokines, myoglobin, free hemoglobin, bilirubin, bile acids, certain toxins, and even metals.

Adsorption Mechanism

CytoSorb operates on primarily hydrophobic binding mechanisms. Its beads are tailored to capture molecules based on size and chemical properties, effectively reducing the levels of circulating inflammatory mediators. Notably, although CytoSorb is highly effective in removing various cytokines and inflammatory proteins, its design does not support significant endotoxin adsorption, which differs markedly from Oxiris.

Clinical Applications and Integration

Integration within CRRT Systems

Oxiris is typically integrated into standard CRRT circuits. This integration is particularly beneficial for septic patients who also develop acute kidney injury (AKI). Since CRRT is a common therapy in intensive care units for patients with AKI, the multifunctional design of Oxiris—combining renal replacement with adsorptive functions—allows a single device to target both uremic toxins and inflammatory mediators. Clinical evidence suggests that this dual-action can improve hemodynamic stability, reduce the need for vasopressors such as norepinephrine, and potentially lower C-reactive protein (CRP) and interleukin-6 (IL-6) levels.

Use in Various Extracorporeal Circuits

In contrast, CytoSorb is notable for its flexibility and can be integrated into a variety of extracorporeal circuits. Its application is not limited to CRRT; it is also used in settings such as cardiopulmonary bypass (CPB), extracorporeal membrane oxygenation (ECMO), and stand-alone hemoperfusion. This versatility allows clinicians to apply CytoSorb in instances where the primary objective is the reduction of cytokine levels, irrespective of whether the patient is concurrently receiving renal replacement therapy.

Comparative Clinical Outcomes

Efficacy in Removing Inflammatory Mediators

Both devices have been shown to remove multiple cytokines and inflammatory mediators from the blood. However, nuances in their performance emerge when evaluating specific inflammatory markers:

• Endotoxin Removal: Oxiris has a distinct advantage in that it efficiently removes endotoxins, which play a pivotal role in the pathogenesis of sepsis, particularly in infections caused by gram-negative bacteria. This capability is primarily due to its ionic adsorption properties and PEI surface treatment.
• Cytokine and Mediator Removal: Both Oxiris and CytoSorb effectively lower cytokine levels. However, the spectrum of substances removed can differ with CytoSorb being adept at clearing a wider array of inflammatory proteins and substances such as chemokines, anaphylatoxins, and even certain drug molecules due to its hydrophobic binding mechanism.

Impact on Mortality and Morbidity

Clinical studies have reported contrasting outcomes based on the use of these devices:

• Oxiris: In some trials, Oxiris usage has been associated with lower 28-day mortality, shortened intensive care unit (ICU) stays, and reduced Sequential Organ Failure Assessment (SOFA) scores. Moreover, the device’s ability to simultaneously manage renal failure and modulate the inflammatory cascade contributes to its favorable performance in clinical settings, particularly in septic shock where endotoxins are prevalent.
• CytoSorb: CytoSorb’s primary impact has been documented in its robust cytokine clearance, making it a suitable intervention for patients experiencing cytokine storms, irrespective of renal failure. Its performance might be especially pivotal in cases with extreme cytokine elevations, although the evidence continues to evolve with ongoing studies.

Treatment Parameters and Duration

The operational protocols differ between the two:

• Oxiris: The filter is typically usable for up to 24 hours and, in some protocols, may be used for as long as 72 hours. The dosing is generally prescribed at more than 35 ml/kg/h, with compatibility with CRRT systems like Baxter’s PrismaFlex and PrisMax being a key feature.
• CytoSorb: This device is usually employed for 24 hours per session and might be continued for daily treatments over a span ranging from 2 to 7 days, depending on the severity and clinical response. Its flexible application allows it to be used in myriad extracorporeal settings.

Detailed Comparison Table

Practical Considerations

Device Characteristics and Setup

The choice between using Oxiris and CytoSorb is often contingent on practical clinical scenarios:

• Integration with CRRT: Oxiris shines in situations where the patient requires kidney replacement therapy. Its integrated design simplifies management by reducing the need for multiple circuits.
• Flexibility: CytoSorb's capacity to be deployed across multiple extracorporeal circuits offers a flexible alternative for managing hypercytokinemia in various clinical settings beyond renal failure.
• Cost and Resource Allocation: The relative cost-effectiveness and local availability of each device may differ by institution and geographic region. Institutional protocols, based on clinical outcomes and experience, are important determinants when selecting a device.
• Regulatory Guidelines: Decisions should be informed by evolving regulatory standards and clinical guidelines, which may favor one technology over the other based on emerging data.

Safety and Tolerability

Both Oxiris and CytoSorb are designed with safety in mind. Their use is generally well tolerated when operated by experienced critical care teams. Special care is required to monitor patients for potential complications:

• Oxiris: Side effects can include filter clotting and the need to monitor anticoagulation parameters due to its integration with CRRT. However, the heparin coating helps mitigate thrombogenic risks.
• CytoSorb: While highly effective in removing cytokines, there have been reports of mild plasma protein loss and alterations in platelet counts, such as transient thrombocytopenia. Continuous monitoring is essential to balance removal efficiency with these potential side effects.

Research Evidence and Clinical Studies

Overview of Clinical Evidence

Both devices have been the subject of clinical research, though the quality of evidence has often been characterized as low to very low, largely due to the challenges of conducting large-scale, randomized controlled trials in critically ill populations. Despite these limitations, several observational studies and case series have provided insight into their utility:

• Oxiris: Studies have noted improvements in clinical parameters such as reduced vasopressor requirements, lower inflammatory marker concentrations, and more favorable SOFA scores, correlating with improved overall patient outcomes and shorter ICU stays.
• CytoSorb: Research highlights its efficacy in diminishing levels of cytokines like IL-6, IL-10, and TNF-α. It is especially pivotal in conditions characterized by a cytokine storm, though further studies are warranted to fully characterize its impact on mortality.

Longevity and Efficacy Considerations

Clinicians weigh both duration of use and the magnitude of therapeutic effect when choosing between these modalities. Oxiris, with its combined functionality, is often utilized as a short-term intervention to manage acute septic crises in patients with simultaneous renal failure. CytoSorb, with its capacity to run over several sessions, allows sustained cytokine clearance in complex inflammatory states, proving beneficial in certain patient populations that do not necessarily have renal impairment.

Summary and Clinical Decision Points

Overview of Key Decision Factors

In clinical practice, the decision regarding which device to employ—Oxiris or CytoSorb—depends on:

• Patient Condition: For septic patients with concurrent acute kidney injury, the all-in-one integration of Oxiris into CRRT systems is highly beneficial for clearing endotoxins and cytokines. In contrast, for patients experiencing a severe cytokine storm without renal compromise or when a broader range of inflammatory mediators must be managed, CytoSorb offers a flexible and effective alternative.
• Timing and Duration of Treatment: The treatment duration and operational setup may vary. Oxiris is generally instituted over relatively short time frames for immediate impact, whereas CytoSorb may be applied continuously or in sessions over several days based on patient responses.
• Overall Clinical Goals: When the clinical objective prioritizes simultaneous renal and inflammatory intervention, the multifaceted nature of Oxiris is advantageous. Conversely, if the primary goal is to mitigate an overwhelming cytokine cascade, the specialized adsorption capabilities of CytoSorb might be preferable.

Conclusion and Final Thoughts

In conclusion, both Oxiris and CytoSorb offer critical solutions in managing the complex pathophysiology of sepsis, septic shock, and hyperinflammatory conditions. Their mechanisms of action, integration into extracorporeal circuits, and clinical outcomes are influenced by their unique design features and the specific needs of the patient.

Oxiris, with its modified AN69 membrane, delivers dual action by efficiently removing both endotoxins and cytokines. This makes it particularly useful in cases of gram-negative sepsis where endotoxin clearance is crucial, and in patients requiring continuous renal replacement therapy. Its integrated design simplifies the clinical workflow by addressing renal failure and inflammatory mediator overload with a single device.

CytoSorb, on the other hand, excels in its capacity for aggressive cytokine removal. Its flexible application across various extracorporeal circuits allows it to be deployed in diverse clinical scenarios, particularly when the primary concern is the management of a cytokine storm. The device’s reliance on hydrophobic adsorption mechanisms makes it effective in clearing a vast range of inflammatory mediators, though it lacks the endotoxin removal capability inherent to Oxiris.

Ultimately, the choice between these two devices should be guided by careful evaluation of the patient’s clinical condition, specific therapeutic endpoints, and available infrastructure. Both devices have shown promise in improving clinical outcomes, yet the evidence base calls for further rigorous studies to fully delineate their impact on mortality and long-term recovery. Clinicians should maintain a multidisciplinary approach, continuously monitoring for side effects and adaptations in treatment protocols to ensure optimal outcomes.

The evolution of extracorporeal blood purification remains a dynamic field, with ongoing research likely to further clarify the roles and potential synergistic use of devices like Oxiris and CytoSorb. In the meantime, the decision-making process must be rooted in current guidelines and tailored patient-specific evaluations.

References

• Renal Replacement Techniques in Septic Shock - PMC
• In vitro comparison of the adsorption of inflammatory mediators - PubMed
• Dual Blood Purification with CytoSorb and oXiris in Managing Recurrent Septic Shock
• Managing Recurrent Septic Shock - Critical Care News
• In vitro comparison of the adsorption of inflammatory mediators - PMC
• A Review of Extracorporeal Blood Purification - ASAIO Journal
• Renal Replacement Techniques in Septic Shock - MDPI
• Continuous Renal Replacement Therapy with the Adsorptive oXiris
• LPS Removal with oXiris, Toraymyxin, and CytoSorb - ResearchGate
• Outcomes of Extracorporeal Blood Purification with oXiris
• Adsorptive Therapies in Sepsis and Inflammation - SciELO México
• In vitro Comparison of the Adsorption of Inflammatory Mediators

Recommended

Explore the differences in blood purification strategies for sepsis

Learn more about extracorporeal devices and their clinical efficacy

Investigate CRRT integration with hemodialysis and adsorptive technologies